Clinical-stage biopharmaceutical company developing therapies for autoimmune and neurodegenerative diseases.
Annexon, Inc., a clinical-stage biopharmaceutical innovator, is dedicated to pioneering therapeutics for autoimmune, neurodegenerative, and ophthalmic disorders. Established in 2011 and based in Brisbane, California, the company focuses on leveraging its deep understanding of the complement system, particularly C1q, a pivotal molecule in the classical complement pathway. This approach allows Annexon to target specific disease mechanisms associated with antibody-mediated autoimmune diseases and complement-mediated neurodegeneration.
Central to Annexon's pipeline is ANX005, a monoclonal antibody currently advancing through Phase II/III clinical trials. ANX005 targets conditions such as guillain-barre syndrome, warm autoimmune hemolytic anemia, and neurodegenerative disorders like Huntington's disease and amyotrophic lateral sclerosis. Additionally, Annexon is developing ANX009, undergoing Phase Ib trials for lupus nephritis, and ANX007, in Phase II trials for geographic atrophy, demonstrating its commitment to addressing unmet medical needs across diverse therapeutic areas.
Innovative research also includes ANX105, an investigational monoclonal antibody targeting neurodegenerative indications, and ANX1502, a novel oral small molecule aimed at treating specific autoimmune conditions. Annexon's comprehensive development portfolio underscores its dedication to advancing therapies that improve patient outcomes and quality of life.
With a strategic focus on expanding therapeutic possibilities through rigorous research and development, Annexon continues to push the boundaries of biopharmaceutical innovation. By harnessing cutting-edge science and clinical expertise, the company aims to redefine treatment paradigms and make significant strides in combating complex diseases globally.